Health & Biotech
4D Medical’s technology disrupts century-old procedures AND makes over 90pc profit margin
Health & Biotech
ASX Health Stocks: Memphasys says Felix can separate sperm better than current techniques
Health & Biotech
EZZ looks to Vietnam for growth after returning from Vietbaby exhibition
Health & Biotech
Dimerix raises $8.7 million to advance Phase 3 trial for kidney drug
Health & Biotech
ASX Health Stocks: OncoSil to commence trial; Korea and Malaysia next stops for these biotechs
Health & Biotech
Creso Pharma subsidiary Mernova Medicinal appoints consultant to expedite cannabis exports to Australia and Europe
Health & Biotech
ScoPo’s Powerplays: ASX health stocks… could be worse
Health & Biotech
Weed Week: A ‘shroom boom’ could see psychedelics follow cannabis’ explosive footsteps
Health & Biotech
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Health & Biotech
ASX Health Stocks: Paradigm Bio says drug effective in dogs, HeraMED signs deal in US
Health & Biotech
ASX Health Stocks: Zelira skyrockets 200pc after saying that its drug works better than Pfizer’s Lyrica
Health & Biotech
First UK patients receive MGC Pharma’s CannEpil product
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.